Literature DB >> 30944159

Identification and Characterization of Functional Human Monoclonal Antibodies to Plasmodium vivax Duffy-Binding Protein.

Lenore L Carias1, Sebastien Dechavanne1, Vanessa C Nicolete2, Sokunthea Sreng3, Seila Suon3, Chanaki Amaratunga4, Rick M Fairhurst4, Celia Dechavanne1,5, Samantha Barnes6, Benoit Witkowski7, Jean Popovici7, Camille Roesch7, Edwin Chen8,9, Marcelo U Ferreira2, Niraj H Tolia8,10, John H Adams6, Christopher L King11,12.   

Abstract

Plasmodium vivax invasion of reticulocytes relies on distinct receptor-ligand interactions between the parasite and host erythrocytes. Engagement of the highly polymorphic domain II of the P. vivax Duffy-binding protein (DBPII) with the erythrocyte's Duffy Ag receptor for chemokines (DARC) is essential. Some P. vivax-exposed individuals acquired Abs to DBPII that block DBPII-DARC interaction and inhibit P. vivax reticulocyte invasion, and Ab levels correlate with protection against P. vivax malaria. To better understand the functional characteristics and fine specificity of protective human Abs to DBPII, we sorted single DBPII-specific IgG+ memory B cells from three individuals with high blocking activity to DBPII. We identified 12 DBPII-specific human mAbs from distinct lineages that blocked DBPII-DARC binding. All mAbs were P. vivax strain transcending and targeted known binding motifs of DBPII with DARC. Eleven mAbs competed with each other for binding, indicating recognition of the same or overlapping epitopes. Naturally acquired blocking Abs to DBPII from individuals with high levels residing in different P. vivax-endemic areas worldwide competed with mAbs, suggesting broadly shared recognition sites. We also found that mAbs inhibited P. vivax entry into reticulocytes in vitro. These findings suggest that IgG+ memory B cell activity in individuals with P. vivax strain-transcending Abs to DBPII display a limited clonal response with inhibitory blocking directed against a distinct region of the molecule.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30944159      PMCID: PMC6764764          DOI: 10.4049/jimmunol.1801631

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  70 in total

1.  Isolation of a monoclonal antibody from a malaria patient-derived phage display library recognising the Block 2 region of Plasmodium falciparum merozoite surface protein-1.

Authors:  K M Sowa; D R Cavanagh; A M Creasey; J Raats; J McBride; R Sauerwein; W F Roeffen; D E Arnot
Journal:  Mol Biochem Parasitol       Date:  2001-01-15       Impact factor: 1.759

Review 2.  Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.

Authors:  Ariel Halper-Stromberg; Michel C Nussenzweig
Journal:  J Clin Invest       Date:  2016-01-11       Impact factor: 14.808

3.  Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria.

Authors:  F Zavala; J P Tam; M R Hollingdale; A H Cochrane; I Quakyi; R S Nussenzweig; V Nussenzweig
Journal:  Science       Date:  1985-06-21       Impact factor: 47.728

4.  Expression cloning of human B cell immunoglobulins.

Authors:  Hedda Wardemann; Juliane Kofer
Journal:  Methods Mol Biol       Date:  2013

5.  Ex vivo characterization and isolation of rare memory B cells with antigen tetramers.

Authors:  Bettina Franz; Kenneth F May; Glenn Dranoff; Kai Wucherpfennig
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

6.  Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children.

Authors:  Enmoore Lin; Benson Kiniboro; Laurie Gray; Stuart Dobbie; Leanne Robinson; Annemarie Laumaea; Sonja Schöpflin; Danielle Stanisic; Inoni Betuela; Melinda Blood-Zikursh; Peter Siba; Ingrid Felger; Louis Schofield; Peter Zimmerman; Ivo Mueller
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

7.  Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus.

Authors:  Theodore Oliphant; Michael Engle; Grant E Nybakken; Chris Doane; Syd Johnson; Ling Huang; Sergey Gorlatov; Erin Mehlhop; Anantha Marri; Kyung Min Chung; Gregory D Ebel; Laura D Kramer; Daved H Fremont; Michael S Diamond
Journal:  Nat Med       Date:  2005-04-24       Impact factor: 53.440

8.  Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10.

Authors:  Dominika J Maskus; Susanne Bethke; Melanie Seidel; Stephanie Kapelski; Otchere Addai-Mensah; Alexander Boes; Güven Edgü; Holger Spiegel; Andreas Reimann; Rainer Fischer; Stefan Barth; Torsten Klockenbring; Rolf Fendel
Journal:  Malar J       Date:  2015-07-16       Impact factor: 2.979

9.  Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort.

Authors:  Elise Landais; Xiayu Huang; Colin Havenar-Daughton; Ben Murrell; Matt A Price; Lalinda Wickramasinghe; Alejandra Ramos; Charoan B Bian; Melissa Simek; Susan Allen; Etienne Karita; William Kilembe; Shabir Lakhi; Mubiana Inambao; Anatoli Kamali; Eduard J Sanders; Omu Anzala; Vinodh Edward; Linda-Gail Bekker; Jianming Tang; Jill Gilmour; Sergei L Kosakovsky-Pond; Pham Phung; Terri Wrin; Shane Crotty; Adam Godzik; Pascal Poignard
Journal:  PLoS Pathog       Date:  2016-01-14       Impact factor: 6.823

10.  A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.

Authors:  Neville K Kisalu; Azza H Idris; Connor Weidle; Yevel Flores-Garcia; Barbara J Flynn; Brandon K Sack; Sean Murphy; Arne Schön; Ernesto Freire; Joseph R Francica; Alex B Miller; Jason Gregory; Sandra March; Hua-Xin Liao; Barton F Haynes; Kevin Wiehe; Ashley M Trama; Kevin O Saunders; Morgan A Gladden; Anthony Monroe; Mattia Bonsignori; Masaru Kanekiyo; Adam K Wheatley; Adrian B McDermott; S Katie Farney; Gwo-Yu Chuang; Baoshan Zhang; Natasha Kc; Sumana Chakravarty; Peter D Kwong; Photini Sinnis; Sangeeta N Bhatia; Stefan H I Kappe; B Kim Lee Sim; Stephen L Hoffman; Fidel Zavala; Marie Pancera; Robert A Seder
Journal:  Nat Med       Date:  2018-03-19       Impact factor: 53.440

View more
  7 in total

1.  Variable immunogenicity of a vivax malaria blood-stage vaccine candidate.

Authors:  Sai Lata De; Samuel May; Keshav Shah; Michelle Slawinski; Siriruk Changrob; Shulin Xu; Samantha J Barnes; Patchanee Chootong; Francis B Ntumngia; John H Adams
Journal:  Vaccine       Date:  2021-04-08       Impact factor: 3.641

Review 2.  Progress towards the development of a P. vivax vaccine.

Authors:  Sai Lata De; Francis B Ntumngia; Justin Nicholas; John H Adams
Journal:  Expert Rev Vaccines       Date:  2021-03-04       Impact factor: 5.217

3.  Naturally acquired blocking human monoclonal antibodies to Plasmodium vivax reticulocyte binding protein 2b.

Authors:  Li-Jin Chan; Anugraha Gandhirajan; Lenore L Carias; Melanie H Dietrich; Oscar Vadas; Remy Visentin; Camila T França; Sebastien Menant; Dominique Soldati-Favre; Ivo Mueller; Christopher L King; Wai-Hong Tham
Journal:  Nat Commun       Date:  2021-03-09       Impact factor: 14.919

Review 4.  Monoclonal antibodies for malaria prevention.

Authors:  Maya Aleshnick; Melina Florez-Cuadros; Thomas Martinson; Brandon K Wilder
Journal:  Mol Ther       Date:  2022-04-05       Impact factor: 12.910

5.  Band 3-mediated Plasmodium vivax invasion is associated with transcriptional variation in PvTRAg genes.

Authors:  Katlijn De Meulenaere; Surendra Kumar Prajapati; Elizabeth Villasis; Bart Cuypers; Johanna Helena Kattenberg; Bernadine Kasian; Moses Laman; Leanne J Robinson; Dionicia Gamboa; Kris Laukens; Anna Rosanas-Urgell
Journal:  Front Cell Infect Microbiol       Date:  2022-09-30       Impact factor: 6.073

6.  Dynamics of IgM and IgG responses to the next generation of engineered Duffy binding protein II immunogen: Strain-specific and strain-transcending immune responses over a nine-year period.

Authors:  Camila M P Medeiros; Eduardo U M Moreira; Camilla V Pires; Letícia M Torres; Luiz F F Guimarães; Jéssica R S Alves; Bárbara A S Lima; Cor J F Fontes; Helena L Costa; Cristiana F A Brito; Tais N Sousa; Francis B Ntumngia; John H Adams; Flora S Kano; Luzia H Carvalho
Journal:  PLoS One       Date:  2020-05-07       Impact factor: 3.240

7.  Whole genome sequencing of Plasmodium vivax isolates reveals frequent sequence and structural polymorphisms in erythrocyte binding genes.

Authors:  Anthony Ford; Daniel Kepple; Beka Raya Abagero; Jordan Connors; Richard Pearson; Sarah Auburn; Sisay Getachew; Colby Ford; Karthigayan Gunalan; Louis H Miller; Daniel A Janies; Julian C Rayner; Guiyun Yan; Delenasaw Yewhalaw; Eugenia Lo
Journal:  PLoS Negl Trop Dis       Date:  2020-10-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.